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Abstract
Two knockout mouse models for the autism candidate gene Neurobeachin (Nbea) have been generated independently.
Although both models have similar phenotypes, one striking difference is the dwarf phenotype observed in the
heterozygous configuration of the GH240B model that is generated by the serendipitous insertion of a promoterless human
growth hormone (hGH) genomic fragment in the Nbea gene. In order to elucidate this discrepancy, the dwarfism present in
this Nbea mouse model was investigated in detail. The growth deficiency in Nbea+/2 mice coincided with an increased
percentage of fat mass and a decrease in bone mineral density. Low but detectable levels of hGH were detected in the
pituitary and hypothalamus of Nbea+/2 mice but not in liver, hippocampus nor in serum. As a consequence, several
members of the mouse growth hormone (mGH) signaling cascade showed altered mRNA levels, including a reduction in
growth hormone-releasing hormone mRNA in the hypothalamus. Moreover, somatotrope cells were less numerous in the
pituitary of Nbea+/2 mice and both contained and secreted significantly less mGH resulting in reduced levels of circulating
insulin-like growth factor 1. These findings demonstrate that the random integration of the hGH transgene in this mouse
model has not only inactivated Nbea but has also resulted in the tissue-specific expression of hGH causing a negative
feedback loop, mGH hyposecretion and dwarfism.
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Introduction
NEUROBEACHIN (NBEA) has previously been identified as a
candidate gene for autism spectrum disorder (ASD) based on
associations and linkage studies and patients with monoallelic
inactivation of NBEA [1–8].
To further investigate the function of NBEA, Nbea heterozy-
gous and knockout mouse models have been used. Independently,
two models have been generated in which the Nbea gene is
disrupted [9,10]. The first model was serendipitously generated via
random integration of a construct containing a minimal human
growth hormone (hGH) genomic fragment. In the GH240B
transgenic line this insertion occurred in intron 1 of Nbea leading
to a genuine null allele [10]. Expression of the hGH minigene was
examined and could not be detected. The second Nbea mouse
model was generated by means of the gene-trap vector system
(further referred to as the gene-trap mouse) [9]. Both mouse
models show similar phenotypes in which bi-allelic inactivation of
Nbea results in neonatal paralysis and death. This is caused by a
complete block of evoked neuromuscular synaptic transmission as
was shown in the GH240B Nbea2/2 mice [10]. The GH240B
Nbea+/2 mice also revealed abnormal morphology of dense-core
granules in blood platelets, similar to the first described patient
with NBEA haploinsufficiency. Furthermore, a decrease in several
actin-associated peptides was observed. In addition, these studies
in blood platelets confirmed the important role of NBEA as an A-
kinase anchoring protein, affecting phosphorylation levels of
several PKA substrates [11]. Increased BDNF levels in the
hippocampus of these mice are probably caused by an increased
CREB phosphorylation level as described in b-TC3 cells.
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Behavioral studies in this mouse model showed an autism-like
phenotype with increased repetitive self-grooming behavior,
increased conditioned fear, decreased sociability and a delayed
spatial learning and memory [12]. Studies in the gene-trap mouse
models showed that loss of NBEA leads to an imbalance in
excitatory and inhibitory signaling with a more affected inhibitory
network, an ectopic accumulation of F-actin in the neuronal cell
body, the dendritic shafts and axons and a decrease in surface
levels of GABAA and glutamate receptors [9,13,14]. Reduced
glutamate responsiveness was measured and confirmed in both
lines [13].
One striking difference between both mouse models is the
presence of a dwarf phenotype in Nbea+/2 mice. This growth
deficiency is only present in the GH240B Nbea+/2 mouse model
[10] whereas the gene-trap Nbea+/2 mice have a normal stature
accompanied by a higher body weight due to an increased adipose
tissue mass [15].
In order to elucidate this discrepancy, the dwarf phenotype of
GH240B Nbea+/2 mice was investigated in detail. A growth curve
was generated and the expression of genes in the GH pathway was
measured at mRNA and protein level. Alterations in body
composition were detected via dual-energy X-ray absorptiometry
(DEXA). Pituitary cell numbers were determined and pituitary size
and the ultrastructure of somatotrope cells were examined. The
responsiveness of somatotrope cells to secretagogues was analyzed
in ex vivo cultures of anterior pituitaries. Finally, hGH expression,
which was previously found to be undetectable, was re-examined
in serum, pituitary, hypothalamus, hippocampus and liver.
Materials and Methods
Animals
The GH240B transgenic line [10] was backcrossed for at least
10 generations with C57BL/6JRj mice (Janvier). Mice were
housed in standard cages (wood-shaving bedding) under conven-
tional laboratory conditions (12/12h light/dark cycle, lights on at
8am; 22uC) and were allowed food and water ad libitum. All
experiments were performed with 12 week old male mice unless
otherwise stated.
Ethics statement
All experiments were approved by the ethical research
committee of KU Leuven in accordance with the declaration of
Helsinki (project number P182/2011).
Assessment of a growth curve
Mice were weighed weekly starting at postnatal day 2 until mice
reached adulthood (12 weeks of age). Afterwards, mice were
weighed once a month until they were 1 year of age. In total 10
male Nbea+/+ mice and 17 male Nbea+/2 mice were included.
Whole body dual-energy X-ray absorptiometry (DEXA)
Mice were anesthetized by intraperitoneal injection with
10 mg/kg Xylazine (Rompun, Bayer, Germany) and 100 mg/kg
Ketamine (Ketamine 1000 CEVA, Ceva Sante Animal, Belgium).
The body composition of anesthetized mice (n = 5/genotype) was
measured by DEXA (PIXImus densitometer, Lunar Corp.,
Madison, USA) using ultra-high resolution (0.1860.18 pixels,
resolution of 1.6 line pairs/mm) and software version 1.45.
RNA extraction and quantitative reverse transcription
PCR (qRT-PCR)
RNA of the anterior pituitary, hypothalamus and liver was
extracted with the Nucleospin RNA XS or L kit (Macherey-Nagel,
Germany) according to the manufacturer’s protocol. Per exper-
iment, an equal amount of RNA was reverse transcribed to cDNA
using the iScript cDNA synthesis kit (Bio-Rad, California, USA).
Real-time qRT-PCR was performed using iQ SYBR Green
Supermix (Bio-Rad). 40 cycles of annealing/extension for 1 min at
60uC were carried out with the MyiQ single color real-time PCR
detection system (Bio-Rad). The relative amount of mRNA
expression was calculated using the method of Livak with
normalization to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as reference gene [16]. The primers used are given as
supporting information (Table S1).
Quantification of growth hormone (GH) and insulin-like
growth factor 1 (IGF-1)
Murine (m)GH levels were quantified using the Rat/Mouse
Growth hormone ELISA (Millipore, Darmstadt, Germany)
according to the supplier’s protocol. The content of human
(h)GH was calculated by means of the HGH human direct ELISA
kit (Invitrogen, Paisley, UK) according to the manufacturer’s
instructions. The plasma samples measured were derived from
blood taken at 3 different time points to cover the peak of GH
release in the mouse, namely 09:30 h, 10:00 h and 10:30 h [17].
Hippocampi were dissected and immediately put on 280uC.
Tissue was homogenized in sucrose buffer (3.18 mM sucrose;
4 mM Tris-HCl pH 7.4) containing a protease and phosphatase
inhibitor cocktail (Roche Diagnostics GmBH, Mannheim, Ger-
many). IGF-1 levels in plasma, derived from the blood samples
taken at 10:30 h, (n = 3/genotype) were measured using the
Quantakine ELISA Mouse/Rat IGF-1 Immunoassay (R&D
systems, Minneapolis, USA) according to the supplier’s guidelines.
Transmission electron microscopy (TEM) of somatotrope
cells
Mice were anesthetized with an intraperitoneal injection of
50 mg/kg Nembutal (CEVA Sante Animale, Brussels, Belgium).
After gravitational perfusion of the mice with Karnovsky’s fixative
(2.5% glutaraldehyde, 2% formaldehyde in 0.1 M sodium
cacodylate buffer; pH 7.4), pituitary glands were isolated and
additionally fixed for 2 hours at room temperature, followed by an
overnight immersion at 4uC in Karnovsky’s fixative. After the
samples were washed and postfixed with 1% OsO4, they were
dehydrated through a series of increasing ethanol concentrations
and embedded in epoxy resin. Ultrathin sections (70 nm) were
collected on formvar-coated copper grids and stained with lead
citrate and uranyl acetate.
TEM of adenopituitary tissue sections was performed at 80 kV
using a JEM1400 transmission electron microscope (JEOL, Tokyo,
Japan). All micrographs were acquired on a SIS Quemesa camera
with the same spatial resolution. One pixel corresponds to
12.44 nm. Somatotropes were identified based on their morpho-
logical description as defined in [18].
Quantification of the different hormonal cell types in the
anterior pituitary
This experiment was performed as described before [19].
Briefly, naive mice were euthanized by CO2 asphyxiation followed
by immediate decapitation. The neural and intermediate lobes of
the pituitary were discarded using a stereomicroscope. The
anterior lobe (anterior pituitary) was isolated and dissociated into
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individual cells with trypsin. Cells were resuspended in serum-free
defined medium (SFDM; Invitrogen) and spun down on Cytospin
slides (SuperfrostPlus; Thermo Scientific, Rockford, USA). Cells
were permeabilized with 0.5% saponin (Sigma-Aldrich, St. Louis,
USA) after fixation in 4% paraformaldehyde, and were incubated
overnight with antibodies against murine GH (1/10,000), prolac-
tin (PRL) (1/10,000), adrenocorticotropic hormone (ACTH) (1/
5,000) and a-glycoprotein subunit (aGSU) (1/1,000). Hormone
antisera were obtained from Dr. A. F. Parlow (National Hormone
and Peptide Program, Harbor-UCLA Medical Center, Torrance,
CA). Subsequently, cells were incubated for 1 h with fluorescently
labeled secondary antibodies (Invitrogen; 1/1,000) and 6-diami-
dino-2-phenylindole (DAPI). Images were captured using an
Olympus IX81 microscope. Cells were counted using ImageJ
(NIH, Maryland, USA) in at least 5 random cytospin fields (1,000–
2,000 cells per hormone per group) and the proportions of
immunopositive cells on the total anterior pituitary cells were
determined. To take into account the smaller size of the anterior
pituitary and the correspondingly lower number of total anterior
pituitary cells (about 2-fold, see Results) in the Nbea+/2 GH240B
mice, we calculated the decrease in absolute cell number of the
different cell types (using their proportion and the total number of
anterior pituitary cells obtained per group of mice).
Primary anterior pituitary cell culture and regulated
secretion assay
Primary cultures were generated based on the protocol
described [19]. Briefly, anterior pituitaries were dissected and
dissociated into single cells as reported above. Cells were
resuspended in SFDM, quantified using a Z2 Coulter counter
(Analis, Namur, Belgium), and seeded in cell culture plates with
Primaria surface treatment (BD Biosciences, Bergen County,
USA). Basal GH secretion was defined as the content GH in
SFDM without secretagogues after 2 h incubation, normalized for
the total amount of GH in medium samples plus lysates. cAMP-
induced GH release was measured after a 2 h incubation in
SFDM containing the non-specific inhibitor of phosphodiesterases
3-isobutyl-1-methylxanthine (IBMX; 100 mM) and the adenylate
cyclase activator Forskolin (1 mM). Stimulated secretion was
defined as the amount of GH secreted after stimulation with
IBMX/Forskolin minus basal release and normalized for the total
amount of GH in medium samples plus lysates. Afterwards, cells
were lysed in RIPA buffer (25 mM Tris-HCl pH 7.6; 150 mM
NaCl; 1% NP-40; 1% sodium deoxycholate; 0.1% sodium dodecyl
sulfate) containing a protease and phosphatase inhibitor cocktail.
Immunoblotting
Anterior pituitary, hypothalamus and liver were homogenized
in RIPA buffer containing a protease and phosphatase inhibitor
cocktail. Anterior pituitaries and hypothalami of littermates were
pooled and homogenization was performed manually using a
pellet pestle for 1.5 ml tubes. Liver tissue was homogenized with a
motor-driven Potter-Elvehjem tissue grinder (Wheaton, Millville,
USA). The protein concentration of the samples was quantified
with a BCA protein assay (Thermo Scientific, Rockford, USA).
25 mg of lysate was loaded on a 10% Bis-Tris gel (Bio-Rad,
California, USA). Proteins were transferred to Protran Nitrocel-
lulose membrane (Schleicher&Schuell, Dassel, Germany) and
incubated with antibodies against human GH (hGH) (Abcam,
Cambridge, UK; 1/1,000) and actin (Sigma-Aldrich; 1/5,000),
used for normalization. Afterwards, membranes were incubated
with HRP-conjugated secondary antibody (1/2,000; Dako,
Glostrup, Denmark) and proteins were visualized with western
blotting ECL detection reagent.
Immunofluorescent staining of human GH in total
pituitary
Total pituitaries were dissected, followed by an overnight
fixation in 4% formaldehyde. After rinsing in 70% ethanol,
pituitaries were embedded in paraffin according to standard
procedures. Tissue blocks were cut in 5 mm sections with
subsequent removal of paraffin with Histo-Clear (National
Diagnostics, Hessle, UK) and dehydration through serial ethanol
solutions. Preceding a 30 min block in 10% goat serum in PBS
with 2% BSA, sections were incubated for 20 min in target
retrieval solution, pH 6 (Dako). Sections were incubated for 1.5 h
with mouse anti-hGH antibody (Abcam; 1/1,000) and subse-
quently for 1 h with Alexa 488–labeled anti-mouse antibody
(Molecular probes, Paisley, UK; 1/500) before mounting in
ProLong Gold Antifade Reagent (Dako) containing DAPI.
Immunofluorescence was visualized by Axiovision software (Zeiss,
Heidelberg, Germany) with the Axio Imager Z1 microscope
(Zeiss).
Statistical analysis
Data are presented as mean with standard error of the mean
(SEM). Significance of differences between mean values were
analyzed using (where appropriate) two-tailed t test, analysis of
variance (ANOVA) or repeated measures (RM)-ANOVA proce-
dures with Tukey test post hoc comparison using Statistica version
9.0 (StatSoft, Oklahoma, USA). All statistical tests were performed
with 0.05 as the a level of significance (*: P,0.05, **: P,0.01 and
***: P,0.001).
Results
Reduced body weight of mice heterozygous for Nbea
To characterize the growth retardation of Nbea+/2 GH240B
mice, their body weight was measured from postnatal day 2 until
mice were 1 year old (Figure 1A). The body weight of Nbea+/2
mice was initially significantly lower than the weight of their wild-
type littermates (RM-ANOVA: main effect of genotype:
F(1,25) = 17.3, P,0.001). This dwarf phenotype was apparent
after 4 weeks and became statistically significant starting 7 weeks
after birth and persisted into adulthood. As mice became older,
Nbea+/2 mice showed an increased weight gain in comparison to
Nbea+/+ mice (RM-ANOVA: interaction genotype x age:
F(22,550) = 8.4, P,0.001) (Figure 1A). At 1 year of age, mice
were sacrificed and their body length was measured. Heterozygous
mice were significantly smaller than their wild-type littermates
(t=3.39, P=0.002), despite similar weight (Figure 1B).
Different body composition of Nbea+/+ and Nbea+/2 mice
A significant interaction effect of genotype with age in the body
weight curve might be indicative for alterations in fat percentage of
Nbea+/2 mice. Therefore, the body composition of adult mice was
determined by DEXA. Although the total tissue mass was
significantly lower in Nbea+/2 mice than in Nbea+/+ mice (t=2
7.91, P,0.001) (Figure 1C), Nbea+/2 mice contain an increased
fat mass percentage and an accordingly decreased lean mass
percentage (%fat: t=5.50, P,0.001; %lean: t=25.3, P,0.001)
(Figure 1D and E). In addition, the bone mineral density of
Nbea+/2 mice was significantly lower compared to Nbea+/+ mice
(t=213.1, P,0.001) (Figure 1F).
The GH/IGF-1 axis is affected in Nbea+/2 mice
The observed dwarf phenotype of Nbea+/2 mice in combina-
tion with the altered body composition suggested abnormalities in
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the GH signaling cascade. To assess alterations in the GH/IGF-1
axis, mRNA expression of the relevant genes was analyzed in
anterior pituitaries, hypothalami and livers from adult mice
(Figure 2A). In the hypothalamus, a significant reduction in Gh-
releasing hormone (Ghrh) expression was detected (t=3.91,
P=0.008) (Figure 2B). The expression level of Ghrelin was too
low to be conclusive. The expression levels of somatostatin (Sst), Sst
receptors (Sstr) 4 and 5, and Gh receptor (Ghr) did not significantly
differ between genotypes (Sst: t=1.85, P=0.11; Sstr4: t=1.62,
P=0.15; Sstr5: t=0.18, P=0.86; Ghr: t=22.29, P=0.07). In
the anterior pituitary, a significant decrease in Gh mRNA
expression was accompanied by a significant increase in Ghr
and the most abundantly expressed somatostatin receptor Sstr2
mRNA expression (Gh: t=3.55, P=0.012; Ghr: t=22.96,
P=0.025, Sstr2: t=25.19, P=0.002) (Figure 2C). No significant
differences in the expression level of Ghrh receptor (Ghrhr), Ghrelin
receptor (Ghrlr) and Sstr5 were detected (Ghrhr: t=1.71, P=0.14;
Ghrlr: t=0.09, P=0.86; Sstr5: t=0.41, P=0.70). One of the
main consequences of peripheral GH signaling is the production of
IGF-1 in the liver [20]. Therefore, Igf-1 mRNA levels in the liver
were determined, combined with the quantification of IGF-1
present in plasma. A significant decrease in Igf-1 mRNA in the
liver was detected (t=3.37, P=0.028) which resulted in a
significantly reduced level of IGF-1 in the plasma (t=8.36,
P=0.001) (Figure 2 D and E).
Reduced presence and GH content of somatotrope cells
in Nbea+/2 mice
During microdissection of the anterior pituitaries, abnormal
morphology of the pituitary of Nbea+/2 mice became apparent
(Figure 3A). The size of the anterior pituitary seemed to be
reduced in Nbea+/2 mice, while the size of the neuropituitary
appeared to be unchanged by visual inspection. To assess which
cell types are affected, anterior pituitaries were dispersed into
single cells, fixed, and marker proteins for specific cell types were
fluorescently labeled and immunopositive cells counted. In
Figure 1. Nbea+/2 mice show postnatal, sustained growth retardation and an altered body composition. (A) Male mice were weighed
from postnatal day 2 until week 52. (B) Male mice were sacrificed at 1 year of age revealing a reduced body length of Nbea+/2 mice compared to
Nbea+/+ mice (Nbea+/+ mice: n = 10, Nbea+/2 mice: n = 17). (C–F) DEXA measurements were performed to analyze the body composition (n = 5/
genotype; 12 weeks old). (C) Nbea+/2 mice have a reduced total tissue mass accompanied by an increase in percentage fat mass (D) and a decreased
percentage lean mass (E). (F) Also, the bone mineral density of Nbea+/2 mice was significantly reduced in comparison with Nbea+/+ mice. *: P,0.05,
**: P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0109598.g001
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accordance with the smaller size, a reduction in total anterior
pituitary cell number was detected for Nbea+/2 mice compared to
Nbea+/+ mice (330,000 and 300,000 cells versus 650,000 and
660,000 cells; n = 2/genotype). Furthermore the cell composition
of these anterior pituitaries was assessed and a 55%63 and
55%69 decrease in the absolute number of GH- and prolactin-
(PRL) positive cells, respectively, was detected in the anterior
pituitary of Nbea+/2 mice when compared to control mice
(Figure 3B; n= 2). The number of cells containing adrenocortico-
tropic hormone (ACTH) and aGSU, which is the a-glycoprotein
subunit of the thyroid-stimulating hormone (TSH), follicle-
Figure 2. Alterations in the GH signaling cascade of Nbea+/2 mice. (A) Schematic representation including the members of the GH pathway
of which the mRNA level was measured by qRT-PCR. Black arrows indicate receptor binding, a + or – added to the arrow implicates a stimulation or
inhibition effect, respectively. (B) In the hypothalamus of Nbea+/2 mice, the expression level of Ghrh was significantly reduced. The mRNA level of
Ghrelin was too low to generate conclusive data (n = 4 litters/genotype; 12 weeks old). (C) In the anterior pituitary, the mRNA level of Gh was
significantly decreased in Nbea+/2 mice. Moreover, the expression level of Ghr and Sstr2 was significantly increased in Nbea+/2 mice (n = 4 litters/
genotype; 12 weeks old). (D) The mRNA level of Igf-1 was significantly reduced in the liver of Nbea+/2 mice (n = 3/genotype; 12 weeks old). (E) The
reduced mRNA level is reflected in a decrease of plasma IGF-1 in Nbea+/2 mice (n = 3/genotype; 12 weeks old). Gh: growth hormone; Ghr: Gh receptor;
Ghrh: Gh-releasing hormone; Ghrhr: Ghrh receptor; Sst: somatostatin; Sstr: Sst receptor; Ghrlr: Ghrelin receptor; Igf-1: insulin-like growth factor 1; *: P,0.05,
**: P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0109598.g002
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stimulating hormone (FSH) and luteinizing hormone (LH), is low
and was therefore too variable to allow firm conclusions.
In addition, the total GH content of the anterior pituitary of
Nbea+/2 and Nbea+/+ mice was measured to assess if the GH
content of the remaining somatotrope cells was affected. Based on
the reduced presence of somatotrope cells by approximately 50%,
a similar decrease in GH content per anterior pituitary is expected
if the remaining somatotrope cells contain normal amounts of GH.
However, in Nbea+/2 mice compared to Nbea+/+ mice, a decline in
GH content per anterior pituitary, with a ratio of 1/6.3260.17
was observed, instead of the expected 2-fold (Nbea+/+ mice:
117.0168.5 mg GH per anterior pituitary; Nbea+/2 mice:
18.561.16 mg GH per anterior pituitary; t=11.48, P,0.001;
n = 3/genotype) (Figure 3C).
To investigate any morphological abnormalities of the GH-
producing cells, transmission electron microscopy was performed.
However, the ultrastructure of the somatotrope cells and the large
electron-dense granules containing GH appeared unaffected
(Figure 4).
Normal responsiveness of the somatotrope cells in
Nbea+/2 mice
In order to evaluate the responsiveness of the remaining
somatotrope cells, primary anterior pituitary cell cultures were
generated allowing GH measurements under basal conditions and
after stimulation with IBMX and Forskolin, secretagogues
mimicking the cAMP-stimulating effect of GHRH (Figure 3D)
[21]. Primary cultures of Nbea+/2 mice secreted significantly less
GH compared to Nbea+/+ mice (ANOVA: main effect of
genotype: F(1,18) = 32.3, P,0.001 and post hoc comparison: basal
medium: P,0.001 and stimulated medium: P,0.001) (Fig-
ure 3D). In addition, the remaining GH in the cell lysate was
significantly lower in cell cultures derived from Nbea+/2 mice
(ANOVA: interaction genotype x condition: F(2,18) = 21.0, P,
0.001 and post hoc comparison: cell lysate: P=0.003). Consistent
with a reduced amount of GH per somatotrope cell in Nbea+/2
mice, the total GH content of 200,000 anterior pituitary cells,
defined as the sum of GH in basal and stimulated medium and the
cell lysate, was decreased in Nbea+/2 mice with 71%63 compared
to the total GH content as measured in Nbea+/+ mice (t=5.15,
P=0.002), while the reduction of GH cells was only 55% (see
above). We analyzed the effect on secretion by normalizing the
absolute amount of GH in the medium for their total GH content
and found no significant difference for genotype in basal nor in
stimulated secretion (two-way ANOVA: genotype: F (1,12) = 1.28,
P=0.27; condition: F (1,12) = 1135.9, P,0.0001; interaction
genotype x condition: F (1,12) = 0.212, P=0.65), indicating a
normal responsiveness of GH secretion upon stimulation (Fig-
ure 3D). Taken together, Nbea+/2 anterior pituitary cell cultures
contain less GH but respond normally to secretagogues.
Expression of human GH in the pituitary and
hypothalamus of Nbea+/2 mice
The Nbea mouse model used in this study was generated
serendipitously by integration of a transgenic construct of hGH
into intron 1 of the Nbea gene resulting in a Nbea null allele.
Although the absence of hGH expression in the pituitary was
previously shown by RT-PCR [22] a more extensive analysis of
hGH expression was conducted here.
Relative mRNA expression of hGH was determined in different
tissues (Figure 5A). In the anterior pituitary of Nbea+/2 mice, the
mRNA level of hGH was comparable to Gapdh mRNA levels
while it was undetectable in Nbea+/+ mice (t=13.94, P,0.001).
Although the hGH expression in the hypothalamus was also
significantly higher compared to Nbea+/+ mice (t = 4.48, P=0.01),
the hGH expression was much lower in comparison to the anterior
pituitary, albeit still clearly detectable. The liver of both Nbea+/2
and Nbea+/+ mice contained at best trace levels of hGH mRNA
(t=0.14, P=0.89).
To assess whether the mRNA levels correlated with protein
levels, a western blot of hGH was performed on lysates of the same
tissues (Figure 5B). hGH protein was detected in the anterior
pituitary of Nbea+/2 mice, but not in the hypothalamus and liver.
As expected, no hGH could be detected in anterior pituitary,
hypothalamus and liver of Nbea+/+ mice.
To obtain insight into which lobes of the pituitary express hGH,
immunofluorescent staining of hGH was performed on sections of
the total pituitary. An immunopositive signal was detected in the
anterior and to a lesser extent the intermediate lobe of the pituitary
of Nbea+/2 mice (Figure 5C).
In order to determine the ratio of hGH relative to murine GH
(mGH) in the anterior pituitary of Nbea+/2 mice, an hGH ELISA
was performed on anterior pituitary lysates. In addition, lysates of
Figure 3. Somatotrope cells in Nbea+/2 mice are less numerous
and contain less GH than Nbea+/+mice. (A) The pituitary of Nbea+/2
mice is smaller. More specifically, the anterior pituitary is affected since
the size of the posterior pituitary (dashed line) appears to be
unaffected. (B) Percent change in absolute number of growth hormone
(GH) and prolactin (PRL) immunopositive cells in the anterior pituitary
of Nbea+/2 compared to control mice, shown for 2 experiments
separately (1,000–2,000 cells per hormone were counted per genotype;
the experiment was conducted twice on 12 weeks old male mice). (C) In
addition to the reduced presence of somatotrope cells in the anterior
pituitary of Nbea+/2 mice, they also contained significantly less GH
(n = 3/genotype; 12 weeks old). (D) Primary anterior pituitary cell
cultures of Nbea+/2 mice secrete similar to Nbea+/+ mice under basal
conditions and upon stimulation with IBMX and Forskolin (Stim.), after
we normalized the GH content in the medium for the total GH level in
somatotropes (n = 4/genotype). *: P,0.05, **: P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0109598.g003
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Figure 4. Normal morphology of somatotrope cells of Nbea+/2mice. Electron microscopic views show representative somatotrope cells of 12
weeks old Nbea+/+ and Nbea+/2 mice with no apparent ultrastructural differences. Nu: nucleus of a somatotrope cell.
doi:10.1371/journal.pone.0109598.g004
Figure 5. Presence of hGHmRNA and protein in the pituitary and hypothalamus of Nbea+/2mice. (A) The qRT-PCR data are represented
as Dct values (Gapdh expression) [16]. In Nbea+/2 mice, the highest hGH mRNA levels were detected in anterior pituitary followed by the
hypothalamus. No signal was detected in liver samples of both Nbea+/2 and control mice (n = 3/genotype). (B) Western blot shows that in the
anterior pituitary of Nbea+/2 mice hGH protein is present whereas no hGH could be detected in the hypothalamus and liver. All tissue from Nbea+/+
mice was negative for hGH (n = 3/genotype). (C) Immunofluorescent staining of hGH gives a positive signal in the anterior (A) and intermediate lobe
(I) of the pituitary of Nbea+/2 mice. No signal was detected in the neural lobe (N) of Nbea+/2 mice. (D) The anterior pituitary of Nbea+/2 mice
contained approximately 40 ng hGH, measured by ELISA for hGH. A significant amount of hGH in the hypothalamus of Nbea+/2 mice was detected
(n = 3/genotype). (E) Under basal conditions, a limited amount of hGH was secreted in anterior pituitary cell cultures. Upon stimulation,
approximately half of the total amount of hGH was secreted. No signal of hGH could be detected in all wild-type samples (n = 3/genotype). ND: not
detectable; *: P,0.05, **: P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0109598.g005
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the hypothalamus were included since an ELISA is more sensitive
than a western blot. In the anterior pituitary of Nbea+/2 mice a
total of 3769 ng hGH was present (Figure 5D), leading to an
mGH/hGH ratio of 505. In the hypothalamus of Nbea+/2 mice,
hGH was also detected with the sensitive ELISA (0.1160.01 ng),
but at much smaller amounts than in the pituitary which is
consistent with mRNA data (Figure 5D). It is worth noting that the
signal detected in all wild-type samples was under the detection
limit of the hGH ELISA.
To find out whether hGH is more generally expressed in the
brain, levels were also measured in lysates of the hippocampus
since this region has the highest expression of NBEA. The values
detected in both wild-type and heterozygous mice were below the
detection limit of the ELISA (Figure 5D).
To analyze whether hGH is secreted under basal and stimulated
conditions, the hGH levels were measured in the samples of the
primary anterior pituitary cell cultures. Under basal conditions,
0.9960.10 ng hGH was detected in the medium, just above the
detection limit of the ELISA. After stimulation with IBMX and
Forskolin, 3.360.3 ng hGH is secreted in the medium, which is 79
times less than mGH. The remaining level of hGH in the cell
lysate was 3.560.1 ng hGH (Figure 5E). The signal detected in all
wild-type samples was under the detection limit, thereby excluding
statistical comparison.
To assess whether hGH could be detected in the circulation,
blood samples were taken at 3 different time points, namely
09:30 h, 10:00 h and 10:30 h, encompassing the peak of GH
release in the mouse [17]. No hGH signal could be detected at any
of the 3 time points in both wild-type and heterozygous samples
(data not shown).
Discussion
In this study we have delineated the dwarf phenotype in the
Nbea+/2 GH240B mouse model generated by Su et al [10]. We
have established that Nbea+/2 GH240B mice have an increased
percentage of fat mass concomitant with a decrease in lean mass
and bone mineral density. This phenotype is the result of
alterations in the GH/IGF-1 axis caused by hGH expressed from
the transgene in the pituitary and hypothalamus of Nbea+/2
GH240B mice. GHRH levels in the hypothalamus are suppressed,
resulting in reduced somatotroph stimulation, causing reduced cell
numbers and mGH content.
When the transgenic construct of hGH was accidently inserted
in intron 1 of Nbea, the absence of expression of hGH in the
pituitary was verified by RT-PCR [10,22]. Expression in other
tissues was not examined. The discrepancy between the two
Nbea+/2 mouse models regarding dwarfism prompted us to
reevaluate the expression of hGH, especially since 5 different
transgenic mouse models were generated with the same transgenic
hGH construct and analysis of pituitary mRNA revealed hGH
expression in 3 of these mouse models [22]. Expression of hGH
was unexpected since the two pituitary specific DNase I
hypersensitive sites I and II (HS I and II), which are essential to
drive high levels of somatotrope-specific hGH expression, were not
incorporated in the transgenic construct [22–24]. hGH mRNA
and protein were detected in the anterior pituitary and hypothal-
amus of Nbea+/2 GH240B mice, using qRT-PCR and ELISA.
Most likely, the absence of HS I and II resulted in a minimal
expression of hGH reflecting the basal functions of the proximal
regulatory elements of the hGH gene present in the transgenic
construct [24].
The presence of hGH in the hypothalamus of Nbea+/2
GH240B mice is probably at the basis of the observed GH
deficiency and subsequent dwarfism. Other transgenic mouse
models with targeted expression of hGH in the hypothalamus also
present dwarfism and similar alterations at the level of the pituitary
to Nbea+/2 GH240B mice [25,26]. The proposed molecular
mechanism of their observed dwarf phenotype is a dominant
negative feedback loop in which hGH is capable of binding the
mGH receptor (mGHR) present in the hypothalamus [27,28]. As
a result, Ghrh mRNA in the hypothalamus is significantly reduced
leading to a decrease in pituitary mGh mRNA and protein levels
[25]. Recently, a similar phenotype was observed in the AlfpCre
mouse model in which the entire hGH gene was inserted into the
AlfpCre transgene leading to the presence of hGH protein in the
hypothalamus and pituitary [29,30].
The 500-fold lower levels of hGH in the pituitary compared to
mGH and the undetectable levels in the blood preclude a
significant effect of hGH on IGF-1 production in liver, while the
low expression level of hGH in hypothalamus is apparently
sufficient to locally activate the mGHR and suppress GHRH
expression. A possible explanation can be that, since mGH is not
expressed in hypothalamus and can only activate the mGHR in
this tissue through an endocrine mechanism, the hGH/mGH ratio
in hypothalamus will probably be many times higher than in
pituitary. However, we did not determine this ratio in the
hypothalamus. No hGH was detected in the hippocampus of
Nbea+/2 GH240B mice, the brain region with the highest
expression of Nbea, indicating that expression of hGH is not
directed by the Nbea promoter but promoter elements in the hGH
transgene itself, only activated in specific tissues. This is also
consistent with the fact that the two genes are in opposite
directions [10].
Similar to Nbea+/2 GH240B mice, the total number of GH-
and PRL-producing cells in the pituitary of mice with transgenic
hGH expression in the hypothalamus is reduced whereas other cell
types were unaffected leading to hypoplasia of the pituitary [26].
Pituitary hypoplasia is also present in other mouse models with
affected GHRH signaling, more specifically the Ghrhr deficient
little mice and the Pc1/3 knockout mice in which the maturation
of proGHRH is blocked [31,32]. The selective reduction of GH
and PRL-producing cells has also been observed in a transgenic
rat model with hGH expression under the control of the Ghrh
promoter [33]. The reduction of these two cell populations can be
explained by developmental relationship and/or paracrine inter-
play [34].
The somatotrope cells present in the transgenic mice expressing
hGH in the hypothalamus retain their functional capacity for GH
secretion in ex vivo cell cultures both under basal condition and
upon stimulation with GHRH [26]. In primary cultures of
anterior pituitary cells of Nbea+/2 GH240B mice, Forskolin and
IBMX were applied as secretagogues mimicking the rise in cAMP
caused by GHRHr activation [21]. A similar ratio of stimulated to
basal GH release was measured for both genotypes indicating a
normal responsiveness of the remaining GH-producing cells in
Nbea+/2 mice. The observed reduced presence of GH in the
medium of cell cultures of Nbea+/2 mice, both in basal and
stimulated conditions, is most likely caused by the reduced
presence of somatotrope cells in the anterior pituitary of Nbea+/
2 mice and the lower GH content per GH-producing cell. Since
NBEA has been identified as a negative regulator of regulated
secretion in vitro [35], the ratio of GH released upon stimulation
versus basal release was anticipated to be higher in ex vivo cell
cultures derived from Nbea+/2 mice. A possible explanation for
the similar ratios is that compensatory mechanisms in the
somatotrope cell population of Nbea+/2 GH240B mice mask
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any ex vivo effect of Nbea haploinsufficiency on regulated
secretion.
For the assessment of the mRNA profile of members of the GH
cascade, only the most relevant SST receptors were included,
although 5 different SST receptors are present both in pituitary
and hypothalamus [36]. In the arcuate nucleus of the hypothal-
amus, Sstr4 and 5 were selected due to their predominant
presence on neurons producing GHRH and Ghrelin [36]. In GH
producing cells, Sstr2 and 5 are most highly expressed [37]. Of
note is that Sstr2 and 5 are also expressed in thyrotrophs [38]. The
observed decrease in Ghrh mRNA in the hypothalamus in
combination with the increased mRNA level of Sstr2 in the
anterior pituitary might be at the basis of the reduced mGhmRNA
detected in the anterior pituitary of Nbea+/2 mice. Most likely, in
an attempt to compensate for the decrease in mGH, the mRNA
level of Ghr is elevated in the anterior pituitary of Nbea+/2 mice.
The 85% reduction in mGh in anterior pituitaries of Nbea+/2
mice causes a 50% decrease in Igf-1 mRNA in the liver and a
66% decrease in IGF-1 protein detected in plasma. Reduced
plasma IGF-1 levels correlate with the dwarf phenotype and
increased fat percentage [20].
The dwarf phenotype in the Nbea GH240B mouse model used
in our experiments obfuscates the interpretation of body weight,
although the body weight of 1-year-old Nbea+/2 mice exceeds the
body weight of Nbea+/+ mice. Normal growth was reported for the
Nbea+/2 gene-trap mice and they also have an increased ratio of
adipose tissue resulting in a higher body weight [15]. These
findings suggest that the increase in adipose tissue is correlated
with Nbea haploinsufficiency rather than solely with the method of
generating the Nbea mouse model. However, it cannot be
excluded that the gene-trap insertion has affected the expression
of other genes involved in adipogenesis.
An important issue arising from this study is whether the mouse
model is still useful for studying NBEA function and its role in
ASD. The two models are highly similar with the exception of
growth deficiency. In addition, behavioral studies with the
GH240B mouse model have shown abnormalities in sociability,
and spatial learning and memory and show an increase in
conditioned fear and in repetitive self-grooming behavior, making
this a highly promising model for the study of ASD [12]. However,
we cannot exclude the fact that the disturbed GH/IGF-1 axis
contributes to the behavioral abnormalities since low IGF-1 levels
have been suggested to contribute to the development of ASD in a
subgroup of patients [39,40] and SHANK3-deficient ASD patients
are being treated with IGF-1 in a clinical trial (Clinicaltrial.gov
NCT01525901). On the other hand, no growth retardation nor
IGF-1 deficiency has been reported in any of the NBEA
haploinsufficient ASD patients and another study in children with
ASD measured an increased level of IGF-1 instead of a decrease,
making the influence of IGF-1 in ASD a controversial issue that
should be further assessed [41]. Behavioral studies in the other
Nbea knockout model and/or the mouse models expressing
transgenic hGH should be performed to exclude the role of hGH
in the behavioral phenotype. To the best of our knowledge, there
are no documented patients with isolated congenital growth
hormone deficiency that also have psychiatric disorders. There-
fore, we assume that the ASD-like phenotype in our mouse model
can be attributed to NBEA haploinsufficiency.
Another argument highlighting the usefulness of the GH240B
model is that abnormalities in platelet morphology, which were
first noticed in several ASD patients including one with NBEA
haploinsufficiency, are also observed in platelets of this mouse
model [11]. This study has also demonstrated an altered
phosphorylation pattern of PKA substrates. Since Nbea is an
AKAP, these results suggest that this mouse model may be most
useful in the identification of PKA substrates whose phosphory-
lation is regulated by Nbea. The first such PKA substrate that was
identified using this mouse model is the transcription factor CREB
[12].
Conclusion
This study has unveiled the molecular basis for the discrepancy
between the two commonly used mouse models for NBEA
deficiency. Despite the growth deficiency caused by recombinant
hGH expression, the two Nbea mouse models are mostly
comparable. Taken together, this correlation between the two
mouse models, combined with correlations with the ASD patient
and cell lines, gives credence to all findings regarding NBEA
function. However, to exclude the confounding effects of hGH we
recommend using the gene-trap mouse models in the future to
study the physiological function of NBEA and its role in the
pathogenesis of ASD.
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Gh receptor; Ghrh: Gh-releasing hormone; Ghrhr: Ghrh receptor;
Sst: somatostatin; Sstr: Sst receptor; Ghrelinr: Ghrelin receptor;
hGH: human GH; Igf-1: insulin-like growth factor 1; Gapdh:
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